Hollings Headlines // July 2021 |
|
Hollings celebrates new ranking |
|
See what Hollings senior leadership has to say about the latest
national ranking in cancer care for MUSC Health.
|
|
“We are delighted to be ranked in the top 40 in the nation for cancer care at MUSC Health. MUSC Hollings Cancer Center serves as the state’s only NCI-designated cancer center and is charged to deliver cutting-edge cancer treatments to a culturally diverse population. We have an amazing team of more than 110 cancer researchers across 20 academic departments doing transdisciplinary research in the lab each day. We know the impact of cancer on patients’ lives, and we’re developing new and better ways to prevent, diagnose and treat cancer.”
- Raymond N. DuBois, M.D., Ph.D., Director of Hollings Cancer Center
|
|
“The rankings show the high-quality work being done at Hollings to deliver the best care for our patients. I’m excited to be in my new roles at Hollings and MUSC, and I’m dedicated to expanding our clinical trials and aggressively recruiting the best clinicians in the nation. I’m deeply grateful to our staff on the front lines who have helped Hollings achieve these rankings and who are there day in and day out helping cancer patients through their journeys. I look forward to being part of how we'll continue to advance cancer care in our state and nation and make a positive impact on the quality of life for our patients.”
- Craig Lockhart, M.D., Hollings Chief of Hematology & Oncology
|
|
Giving patients new hope and a life in remission |
|
A clinical trial at MUSC Hollings Cancer Center is being hailed as a game-changer by doctors for certain leukemia and myelodysplastic syndrome (MDS) patients.
James Deer, 62, became ill in 2018 and was diagnosed with MDS, a rare form of bone marrow failure with few treatment options.
|
|
“Deer achieved what we could call a complete response. A complete response is where his bone marrow shows no signs of MDS. There is no more dysplasia in his bone marrow, and all of his blood counts have returned to normal after starting this trial.”
-Praneeth Baratam, MBBS, Hollings researcher and physician
|
|
Picking the right sunscreen |
|
Andrea Abbott, M.D., is taking time out of her busy schedule to educate people on how to prevent skin cancer. Beyond wearing protective clothing and limiting sun exposure, picking the right sunscreen is critical, particularly given the latest news of recalls of sunscreens.
|
|
Cancer Chat podcast feature
Join us for MUSC Hollings Cancer Center's Cancer Chat podcast. This month, hear from Hugh Royer, a professional golfer, who opens up about his battle with skin cancer, and why he is so thankful for Hollings. Dr. Andrea Abbott also shares important tips to stay safe in the sun, and details what you should look for when selecting the right sunscreen.
|
|
FDA proposes possible ban on menthol cigarettes |
|
Weighing in on an FDA proposal to ban menthol cigarettes and flavored cigars in the United States, a Hollings researcher said the move could save millions of lives, including many minorities and teens who are susceptible to menthol and flavored cigars.
Dr. Michael Cummings: “When you breathe in menthol cigarette smoke, it cools the airways, so it gives a less harsh impression. You can make the argument that it’s actually facilitating nicotine addiction because getting the nicotine out of the smoke and into the lungs is critical to the rapid uptake in nicotine, where it has its effect in the brain.”
|
|
Survivors find power in numbers
|
|
Cancer survivor Joann Baldwin never thought she’d find herself with boxing gloves on or roaming through an urban farm. An innovative wellness program has had her doing both, giving her a way to connect with others while improving her physical and mental health and diet. |
|
Dr. Benjamin Toll will serve as the Associate Director of Education and Training for MUSC Hollings Cancer Center. Toll, a professor of Public Health Sciences and Psychiatry at MUSC, specializes in the treatment of tobacco use disorders and improvement of health behaviors. His goal is to provide effective education and training opportunities for pre-and post-doctoral students and junior faculty at Hollings Cancer Center.
|
|
Dr. Jennifer Dahne will be serving as the interim co-leader of Hollings’ Cancer Control program. She is dedicated to working with program members to foster innovative cancer control research. Dahne joined the MUSC faculty in 2018, and she is currently an associate professor in the Department of Psychiatry and Behavioral Sciences, Addiction Sciences Division.
|
|
LOWVELO 2021 is approaching fast! |
|
Don't forget to register for this year's LOWVELO 2021 ride. The annual fundraiser for MUSC Hollings Cancer Center is back in person and better than ever. We have updated our routes and options to offer something for the whole family. As always, 100% of rider-raised money supports life-saving research at Hollings. This year's event is on November 6th!
Mark your calendars for Glow Blue Week for fun giveaways, free registration, and more!
Monday, August 30th - 11 a.m. to 3 p.m. at Drug Discovery building
Tuesday, August 31st: 10 a.m. to 2 p.m. at MUSC Greenway
Wednesday, September 1st: 4 pm. to 7 p.m. at MUSC Wellness Center
Thursday, September 2nd: 4 p.m. to 7 p.m. at MUSC Greenway
Friday, September 3rd: 4 p.m. to 7 p.m. at Hometeam BBQ Downtown
Stay tuned for more details!
|
|
Send us your news
Got news? We have outlets, from our news site to our video boards! We’d love to help promote your latest journal publications, grants, clinical advances, awards, events and patient stories. Please contact the Hollings communications team to share your news or if you have questions. |
|
Know someone who might be interested in receiving the latest cancer stories and research in their inbox? Forward this email to a friend! |
|
|
Hollings publications and featured trials |
|
|
|
|
|
|
